These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 34447374)
1. COVID-19 Vaccination in Fragile Patients: Current Evidence and an Harmonized Transdisease Trial. Agrati C; Di Cosimo S; Fenoglio D; Apolone G; Ciceri F; Ciliberto G; Baldanti F; Costantini M; Giannarelli D; Ippolito G; Locatelli F; Mantovani A; Morrone A; Tagliavini F; Uccelli A; Zinzani PL; Silvestris N; Rescigno M Front Immunol; 2021; 12():704110. PubMed ID: 34447374 [TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and Safety of the BNT162b2 mRNA COVID-19 Vaccine Among Actively Treated Cancer Patients. Ligumsky H; Safadi E; Etan T; Vaknin N; Waller M; Croll A; Nikolaevski-Berlin A; Greenberg I; Halperin T; Wasserman A; Galazan L; Arber N; Wolf I J Natl Cancer Inst; 2022 Feb; 114(2):203-209. PubMed ID: 34453830 [TBL] [Abstract][Full Text] [Related]
3. Cellular immunity predominates over humoral immunity after homologous and heterologous mRNA and vector-based COVID-19 vaccine regimens in solid organ transplant recipients. Schmidt T; Klemis V; Schub D; Schneitler S; Reichert MC; Wilkens H; Sester U; Sester M; Mihm J Am J Transplant; 2021 Dec; 21(12):3990-4002. PubMed ID: 34453872 [TBL] [Abstract][Full Text] [Related]
4. A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study. Lasagna A; Agustoni F; Percivalle E; Borgetto S; Paulet A; Comolli G; Sarasini A; Bergami F; Sammartino JC; Ferrari A; Zavaglio F; Arena F; Lilleri D; Secondino S; Falzoni M; Schiavo R; Klersy C; Lo Cascio G; Cavanna L; Baldanti F; Pedrazzoli P; Cassaniti I ESMO Open; 2021 Oct; 6(5):100272. PubMed ID: 34543863 [TBL] [Abstract][Full Text] [Related]
5. COVID-19 vaccine use in immunocompromised patients: A commentary on evidence and recommendations. Duly K; Farraye FA; Bhat S Am J Health Syst Pharm; 2022 Jan; 79(2):63-71. PubMed ID: 34455440 [TBL] [Abstract][Full Text] [Related]
6. Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel. Bar-On YM; Goldberg Y; Mandel M; Bodenheimer O; Freedman L; Kalkstein N; Mizrahi B; Alroy-Preis S; Ash N; Milo R; Huppert A N Engl J Med; 2021 Oct; 385(15):1393-1400. PubMed ID: 34525275 [TBL] [Abstract][Full Text] [Related]
7. Alpha-smooth Muscle Actin Expression in the Stroma Predicts Resistance to Trastuzumab in Patients with Early-stage HER2-positive Breast Cancer. Vathiotis IA; Moutafi MK; Divakar P; Aung TN; Qing T; Fernandez A; Yaghoobi V; El-Abed S; Wang Y; Guillaume S; Nuciforo P; Huober J; Di Cosimo S; Kim SB; Harbeck N; Gomez H; Shafi S; Syrigos KN; Fountzilas G; Sotiriou C; Pusztai L; Warren S; Rimm DL Clin Cancer Res; 2021 Nov; 27(22):6156-6163. PubMed ID: 34465600 [TBL] [Abstract][Full Text] [Related]
8. Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2 : A Prospective Cohort Study. Deepak P; Kim W; Paley MA; Yang M; Carvidi AB; Demissie EG; El-Qunni AA; Haile A; Huang K; Kinnett B; Liebeskind MJ; Liu Z; McMorrow LE; Paez D; Pawar N; Perantie DC; Schriefer RE; Sides SE; Thapa M; Gergely M; Abushamma S; Akuse S; Klebert M; Mitchell L; Nix D; Graf J; Taylor KE; Chahin S; Ciorba MA; Katz P; Matloubian M; O'Halloran JA; Presti RM; Wu GF; Whelan SPJ; Buchser WJ; Gensler LS; Nakamura MC; Ellebedy AH; Kim AHJ Ann Intern Med; 2021 Nov; 174(11):1572-1585. PubMed ID: 34461029 [TBL] [Abstract][Full Text] [Related]
9. Detection of SARS-CoV-2 antibodies formed in response to the BNT162b2 and mRNA-1237 mRNA vaccine by commercial antibody tests. Kanji JN; Bailey A; Fenton J; Ling SH; Rivera R; Plitt S; Sligl WI; Taylor S; Turnbull L; Tipples G; Charlton CL Vaccine; 2021 Sep; 39(39):5563-5570. PubMed ID: 34454782 [TBL] [Abstract][Full Text] [Related]
10. Six-Month Efficacy and Toxicity Profile of BNT162b2 Vaccine in Cancer Patients with Solid Tumors. Waldhorn I; Holland R; Goshen-Lago T; Shirman Y; Szwarcwort-Cohen M; Reiner-Benaim A; Shachor-Meyouhas Y; Hussein K; Fahoum L; Peer A; Almog R; Shaked Y; Halberthal M; Ben-Aharon I Cancer Discov; 2021 Oct; 11(10):2430-2435. PubMed ID: 34475136 [TBL] [Abstract][Full Text] [Related]
11. Preemptive Antibody Therapy for Vaccine Breakthrough SARS-CoV-2 Infection in Immunocompromised Patients. Catalano C; Servais S; Bonvoisin C; Couturier B; Hildebrand M; Etienne I; Meuris C; Goffard JC; Wissing M; Goldman M; Le Moine A Transplantation; 2021 Dec; 105(12):e282. PubMed ID: 34456266 [No Abstract] [Full Text] [Related]
12. Peptide Platform as a Powerful Tool in the Fight against COVID-19. Murdocca M; Citro G; Romeo I; Lupia A; Miersch S; Amadio B; Bonomo A; Rossi A; Sidhu SS; Pandolfi PP; Alcaro S; Sangiuolo FC; Novelli G Viruses; 2021 Aug; 13(8):. PubMed ID: 34452531 [TBL] [Abstract][Full Text] [Related]